Sleep Restriction Increases the Risk of Developing Cardiovascular Diseases by Augmenting Proinflammatory Responses via IL-17 and CRP

This small randomized controlled trial subjected 19 healthy volunteers to one week of sleep restriction (approximately 4 hours/night) and measured inflammatory markers — CRP, IL-17, and a panel of other cytokines — compared with a week of normal sleep in a crossover design.

Sleep restriction significantly elevated IL-17 (a pro-inflammatory cytokine associated with autoimmune and inflammatory states) and CRP. Gene expression analysis of peripheral blood cells showed upregulation of inflammatory pathways, including NF-κB signaling, after sleep restriction. The pattern of inflammatory activation resembled that seen in chronic inflammatory conditions.

CRP elevation during sleep restriction is mechanistically significant for cardiovascular risk: CRP is an established independent predictor of cardiovascular events (Ridker et al., 2002), and the CANTOS trial demonstrated that reducing IL-1β-mediated inflammation with canakinumab reduces cardiovascular events — supporting inflammation as a causal CV risk pathway.

The sleep-inflammation-cardiovascular disease axis is mechanistically plausible and consistent with large epidemiological studies showing increased cardiovascular event rates with chronic short sleep. The specific IL-17 pathway identified here adds mechanistic specificity to that association.

At n=19, clinical conclusions must be held lightly, but the controlled experimental design and clear inflammatory signal are reproducible across multiple similar studies in the literature.

We rate the evidence moderate-limited. A small but controlled RCT demonstrating that one week of sleep restriction substantially elevates CRP and IL-17 via pro-inflammatory gene expression pathways — providing experimental mechanistic evidence for sleep deprivation’s cardiovascular risk through chronic inflammation.